Literature DB >> 15344590

A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients.

H Rand Maricq1, I Valter.   

Abstract

OBJECTIVE: To propose a working classification for scleroderma spectrum disorders (SDS), based on criteria shown in the past to be specific for the condition: sclerodermatous skin involvement, specific autoantibodies and specific microvascular abnormalities, to obtain mutually exclusive subgroups of SDS and to test this classification on a sample of patients. This is an attempt to improve the current classifications used in research studies, which are all based on the extent of skin involvement only.
METHODS: Patients (n= 165) referred to the Microvascular Laboratory of the Division of Rheumatology between 1976 and 1992, who had participated in various other studies in the Division and for whom therefore systematically collected clinical and laboratory data were available. Evaluation of skin involvement, clinical, laboratory, and microvascular studies were performed independently and a subgroup assignment was made "blindly" from coded data.
RESULTS: Results demonstrated that significant differences were present between our subgroups of SDS with regard to meaningful variables. Comparisons of our results with previously used classifications such as the ACR preliminary criteria study and later subsets used by more recent investigators, demonstrated that our classification permitted us to include less severe cases than those meeting ACR criteria.
CONCLUSION: Our results show that by dividing SDS into groups using the cutaneous, microvascular and autoantibody characteristics, while using well-defined criteria and inclusion-exclusion rules to obtain mutually exclusive subgroups, can reveal differences that may otherwise be masked. This study has suggested new avenues of research. A replication study should be performed with a systematic follow-up. This is a working classification, i.e. it can be modified as new findings using updated technology become available. The focus should be on clearly defining criteria for classification and collected data. Then between-center comparisons will be possible.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15344590

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  15 in total

1.  New ACR EULAR guidelines for systemic sclerosis classification.

Authors:  Sindhu R Johnson
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

2.  Letter to the editor. Re: Specificity of anti-centromere antibodies for scleroderma.

Authors:  P Roberts-Thomson
Journal:  Rheumatol Int       Date:  2007-06-13       Impact factor: 2.631

Review 3.  [Systemic sclerosis - diagnosis and classification].

Authors:  E Genth; T Krieg
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

4.  Validation of potential classification criteria for systemic sclerosis.

Authors:  Sindhu R Johnson; Jaap Fransen; Dinesh Khanna; Murray Baron; Frank van den Hoogen; Thomas A Medsger; Christine A Peschken; Patricia E Carreira; Gabriela Riemekasten; Alan Tyndall; Marco Matucci-Cerinic; Janet E Pope
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-03       Impact factor: 4.794

Review 5.  [The road to early diagnosis of systemic sclerosis : the evolution of diagnostic and classification criteria in the past decades].

Authors:  M Frerix; F M P Meier; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

Review 6.  [Scleroderma associated autoantibodies - clinical and diagnostic relevance].

Authors:  R Mierau; E Genth
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

Review 7.  Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling.

Authors:  Jennifer L Sargent; Michael L Whitfield
Journal:  Expert Rev Clin Immunol       Date:  2011-07       Impact factor: 4.473

Review 8.  Nailfold video-capillaroscopy in systemic sclerosis.

Authors:  M Cutolo; C Pizzorni; A Sulli
Journal:  Z Rheumatol       Date:  2004-12       Impact factor: 1.372

9.  The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis.

Authors:  Tricia R Cottrell; Robert A Wise; Fredrick M Wigley; Francesco Boin
Journal:  Ann Rheum Dis       Date:  2013-04-20       Impact factor: 19.103

10.  A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity.

Authors:  Jennifer L Sargent; Ausra Milano; Swati Bhattacharyya; John Varga; M Kari Connolly; Howard Y Chang; Michael L Whitfield
Journal:  J Invest Dermatol       Date:  2009-10-08       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.